Alamar Biosciences (ALMR) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 20 102 sessions, April 17, 2026 to September 11, 2026
- Largest daily move
- +30.7% close of August 11, 2026
Company Description
Alamar Biosciences, Inc. develops proteomics technologies for protein detection and analysis. The company’s business centers on its NULISA technology, which stands for NUcleic Acid Linked Immuno-Sandwich Assay, and on a broader Precision Proteomics platform designed to detect and quantify protein biomarkers from small biofluid samples with high sensitivity and specificity.
Alamar sells instruments, consumables, and services based on its proteomic liquid biopsy platform. Its product portfolio includes NULISAseq panels, NULISAqpcr assays, and the ARGO HT fully automated, high-throughput system, which supports a sample-to-answer workflow. The company’s products are used in protein biomarker research, including applications tied to early disease detection and neurodegenerative disease research.
The company operates as a single-segment business focused on developing and commercializing protein-analysis tools. Its revenue model is tied to platform adoption, instrument sales, consumable usage, assay and panel offerings, and related services. Alamar’s customer base includes academic research institutions and biopharmaceutical organizations that use proteomics tools to study disease biology and biomarker signatures.
Alamar Biosciences is incorporated in Delaware and is headquartered in Fremont, California. Its common stock trades on the Nasdaq Stock Market under the symbol ALMR. The company completed its initial public offering in April 2026, after which it adopted amended and restated governing documents as a public company.
Stock Performance
Alamar Biosciences (ALMR) closed at $27.89 on September 11, 2026. Over the past month, the price has lost 23.7%.
ALMR Metrics & Rankings
Price returns through September 11, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Alamar Biosciences has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, partnership, earnings date. View all ALMR news →
SEC Filings
Alamar Biosciences has filed 5 recent SEC filings, including 2 Form SCHEDULE 13G, 1 Form 3, 1 Form 4, 1 Form 8-K. The most recent filing was submitted on September 3, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ALMR SEC filings →
Financial Highlights
Upcoming Events
Fireside chat
Combined dataset completion
Alamar Biosciences has 2 upcoming scheduled events. The next event, "Fireside chat", is scheduled for September 15, 2026 (in 2 days). Investors can track these dates to stay informed about potential catalysts that may affect the ALMR stock price.
Short Interest History
Short interest in Alamar Biosciences (ALMR) currently stands at 2.1 million shares, down 14.6% from the previous reporting period, representing 4.1% of the float. Since April 2026, short interest has increased by 80.0%. This relatively low short interest suggests limited bearish sentiment. The 5.3 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for Alamar Biosciences (ALMR) currently stands at 5.3 days, down 53% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 259.5% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.5 to 11.5 days.
ALMR Company Profile & Sector Positioning
Alamar Biosciences (ALMR) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.